A/Prof Daniel Christ

Daniel Christ is Head of Antibody Therapeutics and Director of the Centre of Targeted Therapy at the Garvan Institute of Medical Research in Sydney, Australia  He trained at the Swiss Federal Institute of Technology (ETH), and at Cambridge University, where he worked with British biotechnology pione
Lab Head - Antibody Therapeutics

Principal Research Fellow

Conjoint/Adjunct Role(s)

Conjoint Associate Professor, St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney
Founder and Chief Scientific Officer, Solvanix Pty Ltd
Director Centre for Targeted Therapy

Daniel Christ is Head of Antibody Therapeutics and Director of the Centre of Targeted Therapy at the Garvan Institute of Medical Research in Sydney, Australia 

He trained at the Swiss Federal Institute of Technology (ETH), and at Cambridge University, where he worked with British biotechnology pioneer Sir Gregory Winter at the MRC Laboratory of Molecular Biology. Winter had shown that in vitro evolution technology (such as phage display) can be used for the generation of therapeutic antibodies, initiating a multi-billion dollar biotechnology industry. At Cambridge, Christ and Winter further developed monoclonal antibody technology, particularly in the field of domain antibodies. He was elected a Fellow of Trinity College (Cambridge University) at age 29 and was involved the foundation of Domantis Ltd (sold to GSK for £230 million in 2006). 

In 2007 Daniel joined the Garvan as Head of Antibody Therapeutics, to translate structural and genomic advances into drug candidates and treatments for cancer and inflammatory conditions. 
His contributions have been recognised by multiple prizes and appointments, including the NHMRC Excellence award, and by the award of more than 15 competitive research grants from the NHMRC and ARC in recent years. 

Christ and co-workers utilise high-troughput selection and sequencing approaches in combination with biochemical and X-ray crystallographic analyses to study and engineer the interaction between therapeutic antibodies and their targets. 

Research Interests

Biotechnology
Antibody therapeutics
Protein engineering
Phage display

Awards and Honours

2013 - NHMRC Excellence Award (top ranked fellowship)
2002 - Fellow, Trinity College, Cambridge University
1999 - ERS PhD Scholarship, Trinity College, Cambridge University
1999 - Swiss Federal Institute of Technology ETH Award

Education

2003 - PhD, Cambridge University - UK
1999 - Dipl Natw (MSc), Swiss Federal Institute of Technology (ETH) - Switzerland

Selected Publications

 

Rodrigo Vazquez-Lombardi, Claudia Loetsch, Daniela Zinkl, Jenny Jackson, Peter Schofield, Elissa K. Deenick, Cecile King, Tri Giang Phan, Kylie E. Webster, Jonathan Sprent and Daniel Christ (2017) Potent antitumour activity of IL-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells. Nature Communications 8:15373

Romain Rouet, David B. Langley, Peter Schofield, Mary Christie, Brendan Roome, Benjamin T. Porebski, Ashley M. Buckle, Ben E. Clifton, Colin L. Jackson, Daniela Stock and Daniel Christ (2017) Structural reconstruction of protein ancestry. Proc Natl Acad Sci USA 14(15):3897-3902

Rodrigo Vazquez-Lombardi, Damien Nevoltris, Ansha Luthra, Peter Schofield, Carsten Zimmermann and Daniel Christ (2017) Transient expression of human antibodies in mammalian cells. Nature Protocols in press 

Rodrigo Vazquez-Lombardi, Tri Giang Phan, Carsten Zimmermann, David Lowe, Lutz Jermutus and Daniel Christ (2015) Challenges and opportunities for non-antibody scaffold drugs.  Drug Discovery Today 20 (10), 1271-1283

Andrew Bradbury et al. (2015) Reproducibility: Standardize antibodies used in research. Nature 518(7537): 27-29 [co-signatory]

Sabouri Z, Peter Schofield, Keisuke Horikawa, Emily Spierings, David Kipling, Katrina L Randall, David Langely, Brendan Roome, Rodrigo Vazquez-Lombardi, Romain Rouet, Jana Hermes, Tyani D Chan, Robert Brink, Deborah K Dunn-Walters, Daniel Christ* and Christopher C Goodnow* (2014) Redemption of autoantibodies on anergic B cells by V-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci USA 111(25): 2567-2575 [*joint senior and corresponding authors]

Romain Rouet and Daniel Christ (2014) Bispecific antibodies with native chain structure. Nature Biotechnology 32(2): 136-7

Domique Gatto, Katherine Wood, Caminschi I, Danielle Murphy-Durland, Peter Schofield, Daniel Christ, Karupiah G and Robert Brink. (2013) The chemotactic receptor EBI2 regulates the homeostasis, localization and immune function of splenic dendritic cells. Nature Immunology 14(5): 446-453

Kip Dudgeon, Romain Rouet, Iris Kokmeijer, Peter Schofield, Jessica Stolp, David Langely, Daniela Stock and Daniel Christ (2012) General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 109: 10879-10884

Romain Rouet, Kip Dudgeon, Peter Schofield, David Lowe, Lutz Jermutus and Daniel Christ (2012) Expression of high affinity antibody fragments in bacteria. Nature Protocols 7: 364-373

Daniel Christ and Greg Winter (2003) Identification of functional similarities between proteins using directed evolution, Proc Natl Acad Sci USA 100:13202-13206

 

Person portrait

A/Prof Daniel Christ